Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.
about
Long-acting beta 2 -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary diseasePrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Pharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewEvidence synthesis for count distributions based on heterogeneous and incomplete aggregated data.Do alternative methods for analysing count data produce similar estimates? Implications for meta-analyses.ICE COLD ERIC--International collaborative effort on chronic obstructive lung disease: exacerbation risk index cohorts--study protocol for an international COPD cohort study.Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCTIntent-to-treat analysis in the presence of off-treatment or missing data.Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.Treatment adherence and health outcomes in patients with bronchiectasis.Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Detecting exacerbations using the Clinical COPD QuestionnaireDaily step count predicts acute exacerbations in a US cohort with COPD.Putting health status guided COPD management to the test: protocol of the MARCH study.Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.The role of bronchodilator treatment in the prevention of exacerbations of COPD.Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trialβ-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocolBudesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations.Long-Term Effects of an Internet-Mediated Pedometer-Based Walking Program for Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial.Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studiesRole of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β2 -Agonists and Inhaled Corticosteroids: The OUTPUL StudyAn official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium.Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious?The impact of psychological distress on exacerbation rates in COPD.Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis.Do we know the minimal clinically important difference (MCID) for COPD exacerbations?Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis.Defining exacerbations in chronic obstructive pulmonary disease.Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis.Predictors of future exacerbation risk in patients with asthma.Duration of Hospitalization and Lung Function Deterioration as Predictors of Future Chronic Obstructive Pulmonary Disease Exacerbations.Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation.Reduced COPD exacerbation risk correlates with improved FEV1: A meta-regression analysis.Clinical and pharmacoeconomic profile of COPD patients with FEV1 50--60% predicted: pilot study on the impact of the extended indication of ICS/LABA.Prospective outcomes in patients with acute exacerbations of chronic obstructive pulmonary disease presenting to hospital: a generalisable clinical audit.Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.Effect of an integrated care programme on re-hospitalization of patients with chronic obstructive pulmonary disease.
P2860
Q24194044-DDE33D32-C864-420C-9688-5163ECFC6EFDQ27348844-6086BF67-970C-4EE8-AC19-73E794B7AFEAQ28070274-148A7E59-F28C-48DE-B752-F5A02BC191ABQ30949429-751F2159-8CBE-47F4-B450-5FC9C0894E52Q31024883-A2167236-301F-48F2-8452-710CA86C1F60Q33440006-CCC2736E-024C-4969-B24C-802B3C11AB4CQ33521100-C9907166-41EC-4ED9-AD01-B5E7D92BA746Q33536518-3E572491-EAA2-4BDF-8507-67447FF14E90Q33796149-7D00719A-A368-43B7-B631-FB09F24C7664Q33877099-3F67C38B-6392-483B-BB5E-36DCDFDCC61DQ34065276-1B8EE668-9F30-493B-AE3F-431770D43583Q34174389-A85D87C9-4EBF-43F3-A78B-B340E73CE829Q34673119-98AAEF40-2319-4B86-AB3B-CCD1818E3FBBQ34798279-F7EA96F7-EA0B-423D-9140-95AAE880EA4EQ36087058-CD9DF126-CC82-4343-9DC1-446865D4E016Q36438669-7259333D-893C-484B-A548-164CE9324B4AQ36444402-19C96362-FF09-4A5F-A1E4-8F0722640E3AQ37006972-F31D0BF4-C4D0-4E46-B4AA-620AD25D5D8DQ37122668-FE631B12-2F87-4862-81F4-5B4A30CBB5F0Q37168340-B2C60751-AEBB-41F6-9368-84FD8B6CC16CQ37195122-F86D2FB9-8713-4465-9949-DC7CD6B728EEQ37199668-D5160809-25EC-429B-915E-1CE52EF8FD93Q37418094-6E26F8A4-42FE-4594-87C8-5F90670FFC72Q37522916-D4937254-3B73-40B0-A50B-E0EDF3C8E86CQ37724621-D1BBD44E-38C1-4354-A43A-BD0D479FACB4Q37776725-A4EAE5F6-07C2-444B-9231-49E2CF750AE4Q37808057-D7033D6C-1D79-4331-BCD5-267D0A2F5420Q37864538-8C3044D8-6D68-49AB-9FDE-10A2B86C6051Q38091512-E89B3547-66B0-4883-8121-E42E3EA60A48Q38219526-8FD104FB-905C-48D2-9448-5751BFB86565Q38503383-274D5DAB-3525-4E25-821B-C44C61BD4B87Q38646619-82F60693-B3FE-4184-9FA9-223F59D54BCFQ38834113-53B5DB47-0ED7-4C6E-9329-565BBB6278F0Q38895033-26C1842B-8DF2-4D02-94C7-604D39473E5FQ39102942-BE2621FC-00FD-4717-8233-8A8ED225E7A7Q39292087-90BF62A3-1D9C-486D-9711-0CAE48EE72BCQ39979584-C76D704B-4F16-4F0C-8DFD-6895560C934CQ40902551-C43C49F7-5327-4C4E-8070-BD9CAE0C16C8Q41400495-86C90403-AC0B-44D6-8758-ABEB4634D33AQ45122322-C9392AC1-1C14-42F9-940A-339589E65CA3
P2860
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.
@en
type
label
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.
@en
prefLabel
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.
@en
P2093
P50
P356
P1433
P1476
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials
@en
P2093
Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium
D O'Donnell
J F Bourbeau
K L Vandemheen
M Fitzgerald
R S Goldstein
S Doucette
P304
P356
10.1136/THX.2007.082636
P407
P577
2007-08-16T00:00:00Z